The Company
Eiffel's focus is on improving the performance and delivery of currently approved pharmaceuticals. The company has extensive experience in the modification and re-engineering of pharmaceutical compounds and are at the forefront of supercritical fluid research.
Supercritical Fluid technologies can be used to produce uniform, very small drug particles. Drugs produced in this way have the potential to be delivered in more convenient and effective dose forms. For example, a drug previously administered via injection could be re-engineered to be delivered via an inhaler. Supercritical Fluid technology is therefore well placed to enable the development of line extension products with superior performance to protect market share once patent life of branded pharmaceuticals expires.
Pharmaceutical development and scale-up activities are conducted at Eiffel’s headquarters in North Ryde, Sydney, Australia.
Pharmaceutical Development Facility
(North Ryde, Sydney, Australia)
On 11 November 2004, Eiffel officially opened its Development Facility and Corporate Offices within the Dow Corning Building in North Ryde.
The facility houses a pilot plant which is designed to overcome the engineering development and scale-up issues faced when transferring laboratory scale processes to a commercial manufacturing environment.
|
|
|
The plant is designed to enable a flexible approach to process development,
and is equipped with significant data logging systems to thoroughly characterise
process parameters and identify those that are critical determinants of product
quality. The plant is also capable of producing batches of re-engineered drug
products at larger scale to support later-stage product development activities.
Eiffel's Origins
Eiffel began operations as a contract manufacturer of pharmaceuticals in 1986 as PharmAction HoldingsLimited and listed on the Australian Stock Exchange in August 1996. In 2001, Eiffel sold its pharmaceutical manufacturing contract operation to Cottee Health.
Since late 2000, Eiffel has focused on developing and commercialising SCF particle re-engineering technologies in partnership with the international drug delivery and pharmaceutical industries. In addition to Eiffel's own patent applications and granted patents, the company was granted in 2000 a world-wide exclusive licence for SCF technology platforms from the Universities of NSW (Unisearch) and Sydney.
The choice of 'Eiffel' as the company name came from some of the earliest research into SCFs. In 1891, French scientist Cailletet generated the high pressures required for SCF processes with a mercury-filled tube extending to the top of the Eiffel Tower.
The Mission
Our mission is to enable the development of better medicines. We aim to build company value and shareholder wealth by utilising our capabilities to develop innovative drug delivery solutions that enable the development of better medicines.
Page updated April 24, 2007